Sleep Apnea Device Receives FDA Approval - Takeaways - MDSpire

Sleep Apnea Device Receives FDA Approval

Randomized trial data support the approval, with sustained improvements in apnea severity observed.

  • By

  • Kathryn Wighton

  • March 19, 2026

  • 2 min

Share

  • 1

    LivaNova PLC received FDA approval for the aura6000 System, a hypoglossal nerve stimulation therapy for obstructive sleep apnea.

  • 2

    The device is indicated for adults with an apnea-hypopnea index between 15 and 65 who cannot tolerate first-line therapies.

  • 3

    The aura6000 System is the first hypoglossal nerve stimulation device approved in the US without contraindications for complete concentric collapse.

  • 4

    In the OSPREY trial, 65% of patients met responder criteria after 12 months, with significant reductions in apnea-hypopnea index.

  • 5

    LivaNova plans to release a next-generation device in 2027, featuring MRI compatibility and a rechargeable battery lasting up to 15 years.

Original Source(s)

Sleep Apnea Device Receives FDA Approval

  • by Kathryn Wighton

  • March 19, 2026

Related Content

Side Effects: Medicine's Blind Spot

Medicine is having a week: new insights on nutrition training, a rethink of “spring fatigue,” evidence that avocados may support artery health, and an AI that can spot rare hormone tumors from a hand photo

New Guidance on Chronic Insomnia Treatment

Experts recommend CBT-I as first-line therapy, with combination treatment reserved for selected patients

Quality of Life in Cardiac Arrest Recovery

Post–cardiac arrest care is increasingly structured around survivorship, with standardized patient-reported assessments supporting multidisciplinary follow-up.